Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (GAAP) - YTD
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue
Total Revenue
Gross Profit
Gross Margin
R&D
R&D percent of Revenues
SG&A
SG&A percent of Revenues
Operating Income
Depreciation
Stock Based Compensation
Net Income
Net Income Margin
EPS³
3Q22-1022
BAUSCH + LOMB 3. On a proforma basis after giving effect to the IPO.
$1,747M
$530M
$495M
$2,772M
$1,484M
53.5%
$229M
8.3%
$1,092M
39.4%
$156M
$98M
$45M
$7M
0.3%
$0.02
3Q21-1Q21
$1,717M
$520M
$527M
$2,764M
$1,464M
53.0%
$201M
7.3%
$1,024M
37.0%
$237M
$90M
$45M
$131M
4.7%
$0.37
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
Reported Change
4. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if
applicable) excluding the impact of acquisitions, divestitures and discontinuations.
2%
2%
(6%)
0%
1%
50 bps
(14%)
(7%)
(34%)
9%
0%
(95%)
Constant Currency²
7%
8%
(3%)
5%
6%
(17%)
(11%)
(29%)
14%
0%
(108%)
Organic Change 2,4
7%
9%
(3%)
5%
33View entire presentation